We retired this podcast, because we couldn't parse it for 10 consecutive times.
In this special series, ReachMD examines the reasons behind the dropping rates of death from heart disease: more effective medications, smarter technologies, more efficient treatment guidelines and much more.
Date | Title & Description | Contributors |
---|---|---|
2022-05-31 | Host: William Boden, MD, FACC, FAHA Patients with ASCVD and a history of MI are at especially high risk for repeat adverse cardiac events. Listen in as Dr. Bill Boden summarizes a post hoc analysis of such patients from the REDUCE-IT trial. Can ic... | |
2022-05-31 | Host: William Boden, MD, FACC, FAHA Patients with ASCVD and a history of MI are at especially high risk for repeat adverse cardiac events. Listen in as Dr. Bill Boden summarizes a post hoc analysis of such patients from the REDUCE-IT trial. Can ic... | |
2022-04-30 |
The 4 Pillars of Treatment in HFrEF: Does Risk of Hyperkalemia Threaten to Topple Them Over? Host: Mikhail Kosiborod, MD Guest: Michael Böhm, MD, FESC The 2022 updates to the ACC/AHA guidelines for heart failure are the first since 2017. In the interim, considerable research has been conducted on the impact of optimal RAASi therapy and ... |
|
2022-04-30 |
From Paper to Patient: Applying Guideline Updates to Practice Host: Marco Metra, MD Guest: Adrian F. Hernandez, MD, MHS Since the 2017 AHA/ACC/HFSA guidelines, considerable research has been conducted in the care of patients with heart failure, including the impact of iron deficiency. The new 2022 guidelin... |
|
2022-04-30 |
From Paper to Patient: Applying Guideline Updates to Practice Host: Marco Metra, MD Guest: Adrian F. Hernandez, MD, MHS Since the 2017 AHA/ACC/HFSA guidelines, considerable research has been conducted in the care of patients with heart failure, including the impact of iron deficiency. The new 2022 guidelin... |
|
2022-04-30 |
The 4 Pillars of Treatment in HFrEF: Does Risk of Hyperkalemia Threaten to Topple Them Over? Host: Mikhail Kosiborod, MD Guest: Michael Böhm, MD, FESC The 2022 updates to the ACC/AHA guidelines for heart failure are the first since 2017. In the interim, considerable research has been conducted on the impact of optimal RAASi therapy and ... |
|
2018-11-30 |
Peripheral Artery Disease: How New Stent Options are Revolutionizing Care Host: Matt Birnholz, MD Guest: William Gray, MD When compared to the options available to coronary artery disease patients, advances in treatment for peripheral artery disease have unfortunately been lacking. But now that’s all changing with the in... |
|
2018-11-30 |
Peripheral Artery Disease: How New Stent Options are Revolutionizing Care Host: Matt Birnholz, MD Guest: William Gray, MD When compared to the options available to coronary artery disease patients, advances in treatment for peripheral artery disease have unfortunately been lacking. But now that’s all changing with the in... |
|
2018-11-12 |
New Options to Reduce Cardiovascular Events in Atherosclerotic Cardiovascular Disease (ASCVD) Host: Peter Libby, MD Host: Michael Miller, MD Guest: Deepak L. Bhatt, MD, MPH Guest: R. Preston Mason, PhD Guest: Børge G. Nordestgaard, MD, DMSc This innovative, 30-minute, CME activity features 5 leading experts addressing complex issues w... |
|
2018-11-08 | Host: John J. Russell, MD Guest: Devi Nair, MD Thanks to recent advancements in technology, physicians are now able to transition from a reactive approach to heart failure treatment to a proactive one. Providing insight into this pivot and the esse... |